amantadine has been researched along with Encephalopathy, Traumatic in 16 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of our study will help to systematically assess the clinical utility of amantadine for treatment of persisting coma in non-traumatic brain injury." | 5.69 | Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES). ( Adeyemi, K; Blum, C; Bösel, R; Brendel, B; Feil, K; Häberle, HA; Haug, I; Hofmann, A; Martus, P; Mengel, A; Rattay, TW; Riessen, R; Schwarz, P; Single, C; Siokas, V; Zago, M; Ziemann, U, 2023) |
| " A retrospective review of electronic medical records was conducted by researchers and data were collected on the following measures: ordered psycho-pharmacological agents, frequency, dosing and duration of orders, whether each administered psycho-pharmacological agent was started before or after psychiatric consultation, and psycho-pharmacological agents prescribed upon discharge." | 2.82 | A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population. ( Kablinger, A; Lemelle, T; Rahmani, E; Sharp, H; Smarbafzadeh, E, 2022) |
| "Traumatic brain injury is a global burden." | 2.82 | Assessment of the effect of amantadine in patients with traumatic brain injury: A meta-analysis. ( Abdelmonem, S; El Sayed, I; Mohamed, MS; Zaki, A, 2022) |
| "Amantadine was found to be well tolerated across the studies." | 2.66 | The role of amantadine in cognitive recovery early after traumatic brain injury: A systematic review. ( El Ammar, F; Goldenberg, FD; Kramer, CL; Lazaridis, C; Loggini, A; Mansour, A; Tangonan, R, 2020) |
| " These results indicate that dosing should be carefully considered when assessing the effects of pharmacotherapies after TBI so that potential benefits are not inadvertently missed." | 1.51 | Dose-dependent neurorestorative effects of amantadine after cortical impact injury. ( Bao, GC; Bleimeister, IH; Bondi, CO; Cheng, JP; Helkowski, MS; Kline, AE; Lam, TR; Okigbo, AA; Royes, BJ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 8 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tracy, BM | 1 |
| Silverman, ME | 1 |
| Cordero-Caballero, C | 1 |
| Durr, EA | 1 |
| Gelbard, RB | 1 |
| Rahmani, E | 1 |
| Lemelle, T | 1 |
| Sharp, H | 1 |
| Smarbafzadeh, E | 1 |
| Kablinger, A | 1 |
| Hofmann, A | 1 |
| Blum, C | 1 |
| Single, C | 1 |
| Adeyemi, K | 1 |
| Schwarz, P | 1 |
| Siokas, V | 1 |
| Rattay, TW | 1 |
| Häberle, HA | 1 |
| Riessen, R | 1 |
| Brendel, B | 1 |
| Haug, I | 1 |
| Bösel, R | 1 |
| Zago, M | 1 |
| Martus, P | 1 |
| Ziemann, U | 1 |
| Mengel, A | 1 |
| Feil, K | 1 |
| Alkhachroum, A | 1 |
| Eliseyev, A | 1 |
| Der-Nigoghossian, CA | 1 |
| Rubinos, C | 1 |
| Kromm, JA | 1 |
| Mathews, E | 1 |
| Bauerschmidt, A | 1 |
| Doyle, K | 1 |
| Velasquez, A | 1 |
| Egbebike, JA | 1 |
| Calderon, AR | 1 |
| Roh, DJ | 1 |
| Park, S | 1 |
| Agarwal, S | 1 |
| Connolly, ES | 1 |
| Claassen, J | 1 |
| Loggini, A | 1 |
| Tangonan, R | 1 |
| El Ammar, F | 1 |
| Mansour, A | 1 |
| Goldenberg, FD | 1 |
| Kramer, CL | 1 |
| Lazaridis, C | 1 |
| Zão, A | 1 |
| Almeida, AF | 1 |
| Beça, G | 1 |
| Nunes, R | 1 |
| Shimia, M | 1 |
| Iranmehr, A | 1 |
| Valizadeh, A | 1 |
| Mirzaei, F | 1 |
| Namvar, M | 1 |
| Rafiei, E | 1 |
| Rahimi, A | 1 |
| Khadivi, A | 1 |
| Aeinfar, K | 1 |
| Mohamed, MS | 1 |
| El Sayed, I | 1 |
| Zaki, A | 1 |
| Abdelmonem, S | 1 |
| Hammond, FM | 1 |
| Sherer, M | 1 |
| Malec, JF | 1 |
| Zafonte, RD | 1 |
| Dikmen, S | 1 |
| Bogner, J | 1 |
| Bell, KR | 1 |
| Barber, J | 1 |
| Temkin, N | 1 |
| Ghalaenovi, H | 1 |
| Fattahi, A | 2 |
| Koohpayehzadeh, J | 1 |
| Khodadost, M | 1 |
| Fatahi, N | 1 |
| Taheri, M | 2 |
| Azimi, A | 1 |
| Rohani, S | 1 |
| Rahatlou, H | 1 |
| Okigbo, AA | 1 |
| Helkowski, MS | 1 |
| Royes, BJ | 1 |
| Bleimeister, IH | 2 |
| Lam, TR | 2 |
| Bao, GC | 1 |
| Cheng, JP | 2 |
| Bondi, CO | 2 |
| Kline, AE | 2 |
| Chen, X | 1 |
| Tang, C | 1 |
| Zhou, H | 1 |
| Li, Z | 1 |
| Wee, TC | 1 |
| Wolff, M | 1 |
| Brooks, DM | 1 |
| Patel, R | 1 |
| Vonder Haar, C | 1 |
| Lam, FC | 1 |
| Adams, WK | 1 |
| Riparip, LK | 1 |
| Kaur, S | 1 |
| Muthukrishna, M | 1 |
| Rosi, S | 1 |
| Winstanley, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Parallel-Group, Randomized, Double-Blind, Placebo-Controlled Trial of Amantadine Hydrochloride in the Treatment of Chronic Traumatic Brain Injury Irritability and Aggression: A Replication Study[NCT00779324] | 168 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients[NCT05479032] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -4 |
| Placebo | -4 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -5 |
| Placebo | -4 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -3 |
| Placebo | -2 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -3 |
| Placebo | -2 |
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00779324)
Timeframe: 28 Days
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | 3.00 |
| Placebo | 3.00 |
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00779324)
Timeframe: 60 days
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | 3.00 |
| Placebo | 3.00 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 66.3 |
| Placebo | 66.7 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 51.3 |
| Placebo | 40.5 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 60.5 |
| Placebo | 48.8 |
As described above for the primary measure, assessed as a secondary measure at Day 60. The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: 60 days
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 74.7 |
| Placebo | 68.3 |
3 reviews available for amantadine and Encephalopathy, Traumatic
| Article | Year |
|---|---|
A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.
Topics: Adrenergic beta-Antagonists; Adult; Aggression; Amantadine; Anticonvulsants; Antipsychotic Agents; B | 2022 |
The role of amantadine in cognitive recovery early after traumatic brain injury: A systematic review.
Topics: Amantadine; Brain Injuries, Traumatic; Cognition Disorders; Humans; Nootropic Agents; Randomized Con | 2020 |
Assessment of the effect of amantadine in patients with traumatic brain injury: A meta-analysis.
Topics: Amantadine; Brain Injuries, Traumatic; Dopamine Agents; Humans | 2022 |
4 trials available for amantadine and Encephalopathy, Traumatic
| Article | Year |
|---|---|
Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES).
Topics: Adult; Amantadine; Brain Injuries; Brain Injuries, Traumatic; Clinical Trials, Phase II as Topic; Co | 2023 |
A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury.
Topics: Amantadine; Brain Injuries; Brain Injuries, Traumatic; Dopamine; Dopamine Agents; Humans; Treatment | 2023 |
Amantadine Did Not Positively Impact Cognition in Chronic Traumatic Brain Injury: A Multi-Site, Randomized, Controlled Trial.
Topics: Adult; Aged; Amantadine; Brain Injuries, Traumatic; Brain Injury, Chronic; Cognition; Dopamine Agent | 2018 |
The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Brain Injuries, Traumatic; Disability Evalua | 2018 |
9 other studies available for amantadine and Encephalopathy, Traumatic
| Article | Year |
|---|---|
Dual Neurostimulant Therapy May Optimize Acute Neurorecovery for Severe Traumatic Brain Injuries.
Topics: Adult; Amantadine; Brain Injuries, Traumatic; Glasgow Coma Scale; Humans; Prospective Studies; Retro | 2021 |
EEG to detect early recovery of consciousness in amantadine-treated acute brain injury patients.
Topics: Amantadine; Brain; Brain Injuries, Traumatic; Consciousness Disorders; Dopamine Agents; Electroencep | 2020 |
[From Vegetative State to Participation: Amantadine As a Trigger of the Rehabilitation Program].
Topics: Adolescent; Amantadine; Brain Injuries, Traumatic; Hospitalization; Humans; Male; Persistent Vegetat | 2020 |
Dose-dependent neurorestorative effects of amantadine after cortical impact injury.
Topics: Amantadine; Animals; Behavior, Animal; Brain Injuries, Traumatic; Dopamine Agents; Dose-Response Rel | 2019 |
Response to letter to the editor: The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial.
Topics: Amantadine; Brain Injuries, Traumatic; Double-Blind Method; Humans | 2019 |
Effect of amantadine on vegetative state after traumatic brain injury: a functional magnetic resonance imaging study.
Topics: Amantadine; Antiparkinson Agents; Brain Injuries, Traumatic; Brain Mapping; Cerebral Cortex; Humans; | 2019 |
Clinical trial on the effects of amantadine on traumatic brain injury outcome. Is there more than meets the eye?
Topics: Amantadine; Brain Injuries, Traumatic; Double-Blind Method; Humans | 2019 |
Environmental enrichment and amantadine confer individual but nonadditive enhancements in motor and spatial learning after controlled cortical impact injury.
Topics: Amantadine; Animals; Brain Injuries, Traumatic; Cognition; Disease Models, Animal; Environment; Male | 2019 |
Frontal Traumatic Brain Injury in Rats Causes Long-Lasting Impairments in Impulse Control That Are Differentially Sensitive to Pharmacotherapeutics and Associated with Chronic Neuroinflammation.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Amantadine; Amphetamine; Animals; Atomoxetine Hydrochlo | 2016 |